03/09/2026
ONE DOSE. THREE MONTHS OF EFFECT?
A Phase 3 trial of Definium Therapeutics’ L*D-based treatment DT120 has produced striking results for people with generalized anxiety disorder.
214 people received either a single 100µg dose of DT120 or placebo.
After 12 weeks, anxiety scores had fallen 11.6 points with DT120 vs 6.2 with placebo — a statistically significant 5.4-point difference.
Improvements were already visible within 48 hours and were sustained throughout the 12-week study.
If a second Phase 3 trial, due to report in September, confirms these findings, L*D could move another step closer to becoming a prescription treatment for anxiety.
Source: Reuters, Kamal Choudhury, Definium says L*D-based pill reduces anxiety in late-stage study, 12 August 2026.
Additional source: Definium Therapeutics Phase 3 Voyage results.
*D